Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy

References

• FerlayJShinHRBrayFFormanDMathersCParkinDMEstimates of worldwide burden of cancer in 2008: GLOBOCAN 2008Int J Cancer2010127122893291721351269
   PubMed Web of Science ®Google Scholar
• SiegelRMaJZouZJemalACancer statistics, 2014CA Cancer J Clin201464192924399786
   PubMed Web of Science ®Google Scholar
• NordlingerBVan CutsemEGruenbergerTEuropean Colorectal Metastases Treatment GroupSixth International Colorectal Liver Metastases WorkshopCombination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panelAnn Oncol200920698599219153115
   PubMed Web of Science ®Google Scholar
• FolprechtGGruenbergerTBechsteinWOTumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trialLancet Oncol2010111384719942479
   PubMed Web of Science ®Google Scholar
• MarcusLLemerySJKhasarSFDA approval summary: TAS-102Clin Cancer Res201723122924292728213365
   PubMed Web of Science ®Google Scholar
• MayerRJVan CutsemEFalconeARECOURSE Study GroupRandomized trial of TAS-102 for refractory metastatic colorectal cancerN Engl J Med2015372201909191925970050
   PubMed Web of Science ®Google Scholar
• EmuraTMurakamiYNakagawaFFukushimaMKitazatoKA novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cellsInt J Mol Med200413454554915010854
   PubMed Web of Science ®Google Scholar
• TanakaNSakamotoKOkabeHRepeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse modelsOncol Rep20143262319232625230742
   PubMedGoogle Scholar
• EmuraTSuzukiNFujiokaAOhshimoHFukushimaMPotentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivoInt J Oncol200527244945516010427
   PubMed Web of Science ®Google Scholar
• BendellJCRosenLSMayerRJPhase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancerCancer Chemother Pharmacol201576592593226370544
   PubMed Web of Science ®Google Scholar
• HongDSAbbruzzeseJLBogaardKPhase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumorsCancer200610761383139016902987
   PubMed Web of Science ®Google Scholar
• OvermanMJVaradhacharyGKopetzSPhase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumorsInvest New Drugs200826544545418528634
   PubMed Web of Science ®Google Scholar
• OvermanMJKopetzSVaradhacharyGPhase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumorsCancer Invest200826879479918798063
   PubMed Web of Science ®Google Scholar
• DoiTOhtsuAYoshinoTPhase I study of TAS-102 treatment in Japanese patients with advanced solid tumoursBr J Cancer2012107342943422735906
   PubMed Web of Science ®Google Scholar
• YoshinoTMizunumaNYamazakiKTAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trialLancet Oncol20121310993100122951287
   PubMed Web of Science ®Google Scholar
• Longo-MuñozFArgilesGTaberneroJEfficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trialClin Transl Oncol201719222723527443414
   PubMedGoogle Scholar
• De AngelisRSantMColemanMPEUROCARE-5 Working GroupCancer survival in Europe 1999–2007 by country and age: results of EUROCARE – 5-a population-based studyLancet Oncol2014151233424314615
   PubMed Web of Science ®Google Scholar
• KotaniDShitaraKKawazoeASafety and efficacy of trifluridine/tipiracil monotherapy in clinical practice for patients with metastatic colorectal cancer: experience at a single institutionClin Colorectal Cancer2016153e109e11526723516
   PubMed Web of Science ®Google Scholar
• MasuishiTTaniguchiHHamauchiSRegorafenib versus trifluridine/tipiracil for refractory metastatic colorectal cancer: a retrospective comparisonClin Colorectal Cancer2017162e15e2227670892
   PubMed Web of Science ®Google Scholar
• WatanabeTMuroKAjiokaYJapanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancerInt J Clin Oncol Epub2017327
   Web of Science ®Google Scholar
• GrotheyAVan CutsemESobreroACORRECT Study GroupRegorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialLancet2013381986330331223177514
   PubMed Web of Science ®Google Scholar
• SuedaTSakaiDKudoTEfficacy and safety of regorafenib or TAS-102 in patients with metastatic colorectal cancer refractory to standard therapiesAnticancer Res20163684299430627466548
   PubMed Web of Science ®Google Scholar
• FukuokaSMoriwakiTTaniguchiHRegorafenib (REG) versus trifluridine/tipiracil (TAS-102) as salvage-line in patients with metastatic colorectal cancer refractory to standard chemotherapies (REGOTAS): a propensity score analysis from a JSCCR multicenter observational studyJ Clin Oncol20173515 Suppl3540
   Google Scholar
• TranBKopetzSTieJImpact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancerCancer2011117204623463221456008
   PubMed Web of Science ®Google Scholar
• DouillardJYOlinerKSSienaSPanitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancerN Engl J Med2013369111023103424024839
   PubMed Web of Science ®Google Scholar
• LenzHNiedzwieckiDInnocentiF501O CALGB/SWOG 80405: phase III trial of irinotecan/5-fu/leucovorin (folfiri) or oxaliplatin/5-fu/leucovorin (mfolfox6) with bevacizumab (bv) or cetuximab (cet) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (mcrc)Ann Oncol201425suppl 4mdu438.13
   Google Scholar
• SuenagaMSchirripaMCaoSGenetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancerAnn Oncol20172851015102228453695
   PubMed Web of Science ®Google Scholar
• YoshinoTShinozakiEYamazakiKEffect of thymidine kinase 1 expression on prognosis and treatment outcomes in refractory metastatic colorectal cancer: results from two randomized studies of TAS-102 versus a placeboJ Clin Oncol2017354 Suppl529
   PubMedGoogle Scholar
• KasiPMKotaniDCecchiniMChemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort studyBMC Cancer20161646727412464
   PubMed Web of Science ®Google Scholar
• TemminkOHHoebeEKvan der BornKAcklandSPFukushimaMPetersGJMechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cellsBr J Cancer200796223124017242697
   PubMed Web of Science ®Google Scholar
• TemminkOHHoebeEKFukushimaMPetersGJIrinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidineEur J Cancer200743117518317049227
   PubMedGoogle Scholar
• NukatsukaMNakagawaFTakechiTEfficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with oxaliplatin on human colorectal and gastric cancer xenograftsAnticancer Res20153594605461526254349
   PubMed Web of Science ®Google Scholar
• NukatsukaMNakagawaFSaitoHSakataMUchidaJTakechiTEfficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenograftsAnticancer Res20153531437144525750295
   PubMed Web of Science ®Google Scholar
• TsukiharaHNakagawaFSakamotoKEfficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenograftsOncol Rep20153352135214225812794
   PubMed Web of Science ®Google Scholar
• BabaYTamuraTSatohYPanitumumab interaction with TAS-102 leads to combinational anticancer effects via blocking of EGFR-mediated tumor response to trifluridineMol Oncol20171181065107728486761
   PubMed Web of Science ®Google Scholar
• SuzukiNTsukiharaHNakagawaFKobunaiTTakechiTEfficacy of trifluridine/tipiracil + anti-mouse PD-1 antibody combination on mouse colorectal cancer model and related tumor immunomodulatory effects [abstract]Proceedings of the American Association for Cancer Research Annual Meeting20172017 April 1–5Washington, DC. Philadelphia (PA)AACR
   Google Scholar
  Cancer Res20177713 Suppl Abstract nr 1071
   Google Scholar
• DoiTYoshinoTFuseNPhase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancerInvest New Drugs20153351068107726163340
   PubMed Web of Science ®Google Scholar
• KubokiYNishinaTShinozakiETAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 studyLancet Oncol Epub2017728
   Google Scholar